JP2021514185A - Ｔ細胞系列の細胞を発生させるための方法 - Google Patents

Ｔ細胞系列の細胞を発生させるための方法 Download PDF

Info

Publication number
JP2021514185A
JP2021514185A JP2020543276A JP2020543276A JP2021514185A JP 2021514185 A JP2021514185 A JP 2021514185A JP 2020543276 A JP2020543276 A JP 2020543276A JP 2020543276 A JP2020543276 A JP 2020543276A JP 2021514185 A JP2021514185 A JP 2021514185A
Authority
JP
Japan
Prior art keywords
cells
cell
notch ligand
primordial
beads
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020543276A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019157597A5 (https=
JP2021514185A5 (https=
Inventor
ジュアン カルロス スニガ−プフルッカー
ジュアン カルロス スニガ−プフルッカー
マフムード モータシャミ
マフムード モータシャミ
アシュトン トロットマン−グラント
アシュトン トロットマン−グラント
Original Assignee
サニーブルック リサーチ インスティチュート
サニーブルック リサーチ インスティチュート
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サニーブルック リサーチ インスティチュート, サニーブルック リサーチ インスティチュート filed Critical サニーブルック リサーチ インスティチュート
Publication of JP2021514185A publication Critical patent/JP2021514185A/ja
Publication of JPWO2019157597A5 publication Critical patent/JPWO2019157597A5/ja
Publication of JP2021514185A5 publication Critical patent/JP2021514185A5/ja
Priority to JP2023191915A priority Critical patent/JP2024016217A/ja
Priority to JP2025216743A priority patent/JP2026031647A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0068—General culture methods using substrates
    • C12N5/0075—General culture methods using substrates using microcarriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/42—Notch; Delta; Jagged; Serrate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
JP2020543276A 2018-02-14 2019-02-14 Ｔ細胞系列の細胞を発生させるための方法 Pending JP2021514185A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023191915A JP2024016217A (ja) 2018-02-14 2023-11-10 Ｔ細胞系列の細胞を発生させるための方法
JP2025216743A JP2026031647A (ja) 2018-02-14 2025-12-02 Ｔ細胞系列の細胞を発生させるための方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862630497P 2018-02-14 2018-02-14
US62/630,497 2018-02-14
PCT/CA2019/050181 WO2019157597A1 (en) 2018-02-14 2019-02-14 Method for generating cells of the t cell lineage

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023191915A Division JP2024016217A (ja) 2018-02-14 2023-11-10 Ｔ細胞系列の細胞を発生させるための方法

Publications (3)

Publication Number Publication Date
JP2021514185A true JP2021514185A (ja) 2021-06-10
JPWO2019157597A5 JPWO2019157597A5 (https=) 2022-02-10
JP2021514185A5 JP2021514185A5 (https=) 2022-02-10

Family

ID=67619677

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020543276A Pending JP2021514185A (ja) 2018-02-14 2019-02-14 Ｔ細胞系列の細胞を発生させるための方法
JP2023191915A Pending JP2024016217A (ja) 2018-02-14 2023-11-10 Ｔ細胞系列の細胞を発生させるための方法
JP2025216743A Pending JP2026031647A (ja) 2018-02-14 2025-12-02 Ｔ細胞系列の細胞を発生させるための方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023191915A Pending JP2024016217A (ja) 2018-02-14 2023-11-10 Ｔ細胞系列の細胞を発生させるための方法
JP2025216743A Pending JP2026031647A (ja) 2018-02-14 2025-12-02 Ｔ細胞系列の細胞を発生させるための方法

Country Status (8)

Country Link
US (2) US12467034B2 (https=)
EP (1) EP3752602A4 (https=)
JP (3) JP2021514185A (https=)
KR (1) KR20200121817A (https=)
CN (1) CN112041431A (https=)
AU (2) AU2019220935B2 (https=)
CA (1) CA3091158A1 (https=)
WO (1) WO2019157597A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021514185A (ja) 2018-02-14 2021-06-10 サニーブルック リサーチ インスティチュート Ｔ細胞系列の細胞を発生させるための方法
JP2023548115A (ja) * 2020-10-28 2023-11-15 サンガモ セラピューティクス， インコーポレイテッド ヒト多能性幹細胞からのｃｄ４＋エフェクターおよび制御性ｔ細胞の生成
WO2022115492A1 (en) * 2020-11-24 2022-06-02 Lyell Immunopharma, Inc. Methods for making, compositions comprising, and methods of using rejuvenated t cells
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
AU2021392032A1 (en) 2020-12-03 2023-06-22 Century Therapeutics, Inc. Genetically engineered cells and uses thereof
KR20230128324A (ko) * 2021-02-05 2023-09-04 고쿠리츠다이가쿠호진 고베다이가쿠 인공 다능성 줄기 세포 유래 γδ T 세포 및 그 제작방법
WO2022216524A1 (en) 2021-04-07 2022-10-13 Century Therapeutics, Inc. Combined artificial cell death/reporter system polypeptide for chimeric antigen receptor cell and uses thereof
CA3210702A1 (en) 2021-04-07 2022-10-13 Century Therapeutics, Inc. Gene transfer vectors and methods of engineering cells
WO2022241558A1 (en) * 2021-05-18 2022-11-24 The University Of British Columbia A method for producing blood progenitor and progenitor t cells, resulting cells and methods and uses thereof
WO2023129937A1 (en) 2021-12-29 2023-07-06 Century Therapeutics, Inc. Genetically engineered cells having anti-cd19 / anti-cd22 chimeric antigen receptors, and uses thereof
IL314801A (en) 2022-02-22 2024-10-01 Juno Therapeutics Inc Proteinase 3 (PR3) Chimeric Autoantigen Receptor T Cells and Related Methods and Uses
CN119365492A (zh) 2022-05-04 2025-01-24 世纪治疗股份有限公司 用hla-e和hla-g转基因工程化的细胞
JP2025522360A (ja) 2022-06-08 2025-07-15 センチュリー セラピューティクス，インコーポレイテッド Ｃｄ１６変異体およびｎｋｇ２ｄを発現する遺伝子操作した細胞ならびにその使用
CA3257650A1 (en) 2022-06-08 2023-12-14 Century Therapeutics, Inc. Immunoeffector cells derived from genetically modified, multipotential stem cells with membrane IL-12 and their uses
WO2023240212A2 (en) 2022-06-08 2023-12-14 Century Therapeutics, Inc. Genetically engineered cells having anti-cd133 / anti-egfr chimeric antigen receptors, and uses thereof
WO2024102838A1 (en) 2022-11-09 2024-05-16 Century Therapeutics, Inc. Engineered interleukin-7 receptors and uses thereof
KR20250143301A (ko) 2022-11-10 2025-10-01 센츄리 쎄라퓨틱스 인코포레이티드 항-넥틴4 키메라 항원 수용체를 갖는 유전자 조작 세포 및 이의 용도
WO2024156066A1 (en) * 2023-01-27 2024-08-02 Notch Therapeutics (Canada), Inc. Method for generating t cell lineage populations from stem/progenitor cells
WO2025101938A2 (en) 2023-11-10 2025-05-15 Century Therapeutics, Inc. Genetically engineered cells having multi-transmembrane domain chimeric antigen receptors utilizing g protein-coupled receptor scaffolds, and uses thereof
WO2025106626A1 (en) 2023-11-15 2025-05-22 Century Therapeutics, Inc. Genetically engineered cells expressing c-x-c chemokine receptor type 4, and uses thereof
WO2025207798A1 (en) 2024-03-26 2025-10-02 Century Therapeutics, Inc. Genetically engineered cells having anti-cd123 chimeric antigen receptors, and uses thereof
WO2025207795A1 (en) 2024-03-26 2025-10-02 Juno Therapeutics, Inc. Genetically engineered cells having anti-cd33 / anti-cd123 chimeric antigen receptors, and uses thereof
US20250332260A1 (en) 2024-04-10 2025-10-30 Garuda Therapeutics, Inc. Immune compatible cells for allogeneic cell therapies to cover global, ethnic, or disease-specific populations

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006506322A (ja) * 2002-04-05 2006-02-23 ロランティス リミテッド 内科療法
JP2006517533A (ja) * 2003-01-23 2006-07-27 ロランティス リミテッド Ｎｏｔｃｈシグナル伝達経路のアクチベーターを用いる自己免疫疾患の治療
WO2007027226A2 (en) * 2005-04-28 2007-03-08 Board Of Regents, The University Of Texas System Systems and methods for the production of differentiated cells
WO2016123100A1 (en) * 2015-01-26 2016-08-04 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
WO2017173551A1 (en) * 2016-04-08 2017-10-12 The Governing Council Of The University Of Toronto Method for generating progenitor t cells from stem and/or progenitor cells and use of same
JP2017531148A (ja) * 2014-09-16 2017-10-19 ヒタチ ゾウセン イノバ アクチェンゲゼルシャフト 廃棄物焼却プラントの燃焼チャンバー内で発生するスラグを処理するための方法及び装置

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100895231B1 (ko) 2002-03-25 2009-05-04 다카라 바이오 가부시키가이샤 세포상해성 림프구의 제조방법
US7575925B2 (en) * 2002-12-10 2009-08-18 Sunnybrook Health Sciences Centre Cell preparations comprising cells of the T cell lineage and methods of making and using them
EP2321407A4 (en) 2008-09-11 2012-07-18 Univ Florida SYSTEM AND METHOD FOR THE PRODUCTION OF T-CELLS
JP5756017B2 (ja) * 2008-11-07 2015-07-29 サニーブルック ヘルス サイエンシズ センター ヒト前駆ｔ細胞
US8871510B2 (en) 2009-12-03 2014-10-28 University Of Utah Research Foundation Methods for generating T lymphocytes from hematopoietic stem cells
ES2608937T3 (es) 2010-02-22 2017-04-17 Université Pierre Et Marie Curie (Paris 6) Medio de cultivo celular para el crecimiento y diferenciación de células del linaje hematopoyético
CN104053769A (zh) * 2011-11-21 2014-09-17 大学健康网络 造血祖细胞群体和富集其干细胞的方法
FR3026744B1 (fr) * 2014-10-06 2024-04-19 Hopitaux Paris Assist Publique Methode de generation de progeniteurs de cellules t
WO2016187459A1 (en) 2015-05-20 2016-11-24 The Regents Of The University Of California Method for generating human dendritic cells for immunotherapy
US20190134169A1 (en) 2016-04-26 2019-05-09 Temple University-Of The Commonwealth System Of Higher Education DLL4-expressing cells and vaccine using the same
IL268641B2 (en) 2017-02-13 2024-10-01 Assist Publique Hopitaux Paris Aphp Method for generating t cells progenitors
JP2021514185A (ja) 2018-02-14 2021-06-10 サニーブルック リサーチ インスティチュート Ｔ細胞系列の細胞を発生させるための方法
EP4326856A4 (en) * 2021-04-23 2025-10-08 Sunnybrook Res Inst STEM CELLS COMPRISING AN UNREARRANGED T CELL RECEPTOR (TCR) GENE LOCUS AND METHODS OF USE THEREOF
WO2022241558A1 (en) * 2021-05-18 2022-11-24 The University Of British Columbia A method for producing blood progenitor and progenitor t cells, resulting cells and methods and uses thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006506322A (ja) * 2002-04-05 2006-02-23 ロランティス リミテッド 内科療法
JP2006517533A (ja) * 2003-01-23 2006-07-27 ロランティス リミテッド Ｎｏｔｃｈシグナル伝達経路のアクチベーターを用いる自己免疫疾患の治療
WO2007027226A2 (en) * 2005-04-28 2007-03-08 Board Of Regents, The University Of Texas System Systems and methods for the production of differentiated cells
JP2017531148A (ja) * 2014-09-16 2017-10-19 ヒタチ ゾウセン イノバ アクチェンゲゼルシャフト 廃棄物焼却プラントの燃焼チャンバー内で発生するスラグを処理するための方法及び装置
WO2016123100A1 (en) * 2015-01-26 2016-08-04 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
WO2017173551A1 (en) * 2016-04-08 2017-10-12 The Governing Council Of The University Of Toronto Method for generating progenitor t cells from stem and/or progenitor cells and use of same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A, vol. 79, no. 3, JPN6022055844, 2006, pages 689 - 697, ISSN: 0005102815 *

Also Published As

Publication number Publication date
AU2019220935B2 (en) 2025-03-20
AU2025204516A1 (en) 2025-07-03
US20200399599A1 (en) 2020-12-24
US12467034B2 (en) 2025-11-11
EP3752602A4 (en) 2021-11-24
JP2026031647A (ja) 2026-02-24
AU2019220935A1 (en) 2020-10-01
JP2024016217A (ja) 2024-02-06
WO2019157597A1 (en) 2019-08-22
US20260043003A1 (en) 2026-02-12
CN112041431A (zh) 2020-12-04
EP3752602A1 (en) 2020-12-23
KR20200121817A (ko) 2020-10-26
CA3091158A1 (en) 2019-08-22

Similar Documents

Publication Publication Date Title
US20260043003A1 (en) Method for generating cells of the t cell lineage
JP7181910B2 (ja) 養子療法用の免疫細胞集団を単離、培養、および遺伝子操作するための方法
Larochelle et al. Identification of primitive human hematopoietic cells capable of repopulating NOD/SCID mouse bone marrow: implications for gene therapy
JP6983771B2 (ja) 幹細胞からｔ細胞を作製する方法および該ｔ細胞を用いた免疫療法的方法
JP2010042011A (ja) ヒト胚性幹細胞の造血分化
MXPA06006706A (es) Celulas madre.
US20200263134A1 (en) Expansion and use of expanded nk cell fractions
EP1687411A2 (en) Hematopoietic stem cell identification and isolation
US12054743B2 (en) Method for obtaining T cells from pluripotent stem cells, and uses thereof
Wang et al. Mouse mesenchymal stem cells can support human hematopoiesis both in vitro and in vivo: the crucial role of neural cell adhesion molecule
US20030100107A1 (en) Compositions and methods for generating differentiated human cells
CN103540566A (zh) 用于长期造血种群恢复的方法和组合物
US20120177618A1 (en) Hematopoietic stromal progenitor cells and uses thereof
WO1998021313A1 (en) Method for culturing hematopoietic stem cells
US20080095746A1 (en) Process For Producing Hematopoietic Stem Cells Or Vascular Endothelial Precursor Cells
Kim et al. Generation of CD34+ cells from human embryonic stem cells using a clinically applicable methodology and engraftment in the fetal sheep model
US20250090578A1 (en) Method of producing a population of immune cells from pluripotent stem cells
US20140154219A1 (en) Methods and compositions for large-scale isolation of very small embryonic-like (vsel) stem cells
Mizokami et al. Preferential expansion of human umbilical cord blood-derived CD34-positive cells on major histocompatibility complex-matched amnion-derived mesenchymal stem cells
Prasad et al. Propagation and characterisation of dendritic cells from G-CSF mobilised peripheral blood monocytes and stem cells in common marmoset monkeys
RU2797260C2 (ru) Способ получения предшественников т-клеток
Wang et al. ĐFerrata Storti Foundation
Kode et al. Mesenchymal stromal cells and their clinical applications
SUPPORTIVE Cord blood oral abstracts
Class et al. Patent application title: HEMATOPOIETIC STROMAL PROGENITOR CELLS AND USES THEREOF Inventors: Biju Parekkadan (Cambridge, MA, US) John Miles Milwid (Cambridge, MA, US) Martin Leon Yarmush (Newton, MA, US) Assignees: Massachusetts Institute of Technology THE GENERAL HOSPITAL CORPORATION d/b/a MASSACHUSETTS GENERAL HOSPITAL

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200930

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210615

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220202

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220202

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230410

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230710